Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. Company also provides devices such as AnsuPen and AnsuPen Twist. The company operates in Bangladesh and sells its products locally and internationally.
1964
12.5K+
LTM Revenue $618M
LTM EBITDA $190M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Square Pharma has a last 12-month revenue of $618M and a last 12-month EBITDA of $190M.
In the most recent fiscal year, Square Pharma achieved revenue of $585M and an EBITDA of $211M.
Square Pharma expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Square Pharma valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $481M | $524M | $585M | $618M | XXX |
Gross Profit | $247M | $258M | $276M | XXX | XXX |
Gross Margin | 51% | 49% | 47% | XXX | XXX |
EBITDA | $189M | $196M | $211M | $190M | XXX |
EBITDA Margin | 39% | 37% | 36% | 31% | XXX |
Net Profit | $152M | $158M | $175M | XXX | XXX |
Net Margin | 32% | 30% | 30% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, Square Pharma's stock price is BDT 216 (or $2).
Square Pharma has current market cap of BDT 192B (or $1.6B), and EV of BDT 146B (or $1.2B).
See Square Pharma trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.2B | $1.6B | XXX | XXX | XXX | XXX | $0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, Square Pharma has market cap of $1.6B and EV of $1.2B.
Square Pharma's trades at 2.0x LTM EV/Revenue multiple, and 6.4x LTM EBITDA.
Analysts estimate Square Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Square Pharma and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $1.2B | XXX | XXX | XXX |
EV/Revenue | 2.0x | XXX | XXX | XXX |
EV/EBITDA | 6.0x | XXX | XXX | XXX |
P/E | 8.7x | XXX | XXX | XXX |
P/E/Growth | 0.8x | XXX | XXX | XXX |
EV/FCF | 10.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSquare Pharma's NTM/LTM revenue growth is 9%
Square Pharma's revenue per employee for the last fiscal year averaged $47K, while opex per employee averaged $10K for the same period.
Over next 12 months, Square Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Square Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Square Pharma and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 12% | XXX | XXX | XXX | XXX |
EBITDA Margin | 33% | XXX | XXX | XXX | XXX |
EBITDA Growth | 7% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 42% | XXX | XXX | XXX | XXX |
Revenue per Employee | $47K | XXX | XXX | XXX | XXX |
Opex per Employee | $10K | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
Opex to Revenue | 21% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Square Pharma acquired XXX companies to date.
Last acquisition by Square Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Square Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Square Pharma founded? | Square Pharma was founded in 1964. |
Where is Square Pharma headquartered? | Square Pharma is headquartered in Bangladesh. |
How many employees does Square Pharma have? | As of today, Square Pharma has 12.5K+ employees. |
Is Square Pharma publicy listed? | Yes, Square Pharma is a public company listed on DHA. |
What is the stock symbol of Square Pharma? | Square Pharma trades under SQURPHARMA ticker. |
Who are competitors of Square Pharma? | Similar companies to Square Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Square Pharma? | Square Pharma's current market cap is $1.6B |
What is the current revenue of Square Pharma? | Square Pharma's last 12-month revenue is $618M. |
What is the current EBITDA of Square Pharma? | Square Pharma's last 12-month EBITDA is $190M. |
What is the current EV/Revenue multiple of Square Pharma? | Current revenue multiple of Square Pharma is 2.0x. |
What is the current EV/EBITDA multiple of Square Pharma? | Current EBITDA multiple of Square Pharma is 6.4x. |
What is the current revenue growth of Square Pharma? | Square Pharma revenue growth between 2023 and 2024 was 12%. |
Is Square Pharma profitable? | Yes, Square Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.